The People
Behind the Science
Our team brings together leading researchers in immunoparasitology, drug development, and biotechnology commercialisation.
Deep expertise in translating early-stage discovery research into new ventures and clinical-stage programmes. Strategic leadership across biotech financing and partnership development.
World-leading expert in helminth biology and hookworm secretomics. Built the foundational IP platform underpinning MBT-001 and MBT-002.
Expert in helminth immunology, clinical trials, and IBD research. Senior Research Fellow at AITHM, JCU. PhD from University of Adelaide.
Over 30 years in investment and financial services, holding senior positions at some of Australia's largest investment banks and financial services organisations. CEO of an investment and philanthropic consultancy and director of multiple private companies.
A member of the investment team at Main Sequence — Macrobiome's lead investor — focused on humanity-scale healthcare. An investment track record spanning 80+ startups across Australia, the US, and Southeast Asia. Former Director of New Ventures and Entrepreneurship at ANU; founder of Blue Sky VC and Tribe Global Ventures. PhD in Biochemistry (Stem Cell Biology), University of Adelaide.
Biopharma veteran with executive roles at Boehringer Ingelheim, Amgen, Theraclone, and Tanox — and postdoctoral training at Genentech. More than 20 drug candidates advanced to clinical testing, with two approvals to date. High-impact publications in immunology and virology. BSc and PhD in Biochemistry from the University of Toronto. Currently engaged in new company creation within the venture capital community.
Held executive positions at Amgen in California, including Executive Director leading a global team spanning biologics, small molecules, cell and gene therapies. Currently Senior Vice President of Therapeutics at Microba Life Sciences. Over 25 years of R&D experience. Former Director of the National Biologics Facility and Director of the ARC Centre for Biopharmaceutical Innovation. Postdoctoral studies at Harvard Medical School and the University of Cambridge. PhD in Protein Biochemistry from UQ.
Extensive pharmaceutical R&D experience in small molecule and biologics-based therapeutics for immunological disorders — including as Senior Director & Head of GI Inflammation Drug Discovery at Takeda Pharmaceuticals and Senior Director of IBD Discovery Research at Janssen Pharmaceuticals. PhD in Biochemistry from the University of Bristol.